mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.015 |
0.6 |
mRNA |
crizotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.016 |
0.7 |
mRNA |
selumetinib:piperlongumine (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.016 |
0.7 |
mRNA |
Vorinostat |
gCSI |
pan-cancer |
AAC |
-0.023 |
0.7 |
mRNA |
Doxorubicin |
CTRPv2 |
pan-cancer |
AAC |
0.013 |
0.7 |
mRNA |
AT13387 |
CTRPv2 |
pan-cancer |
AAC |
-0.021 |
0.7 |
mRNA |
Genentech Cpd 10 |
GDSC1000 |
pan-cancer |
AAC |
-0.014 |
0.7 |
mRNA |
3-Cl-AHPC |
CTRPv2 |
pan-cancer |
AAC |
-0.015 |
0.7 |
mRNA |
NG-25 |
GDSC1000 |
pan-cancer |
AAC |
-0.013 |
0.7 |
mRNA |
tubastatin A |
GDSC1000 |
pan-cancer |
AAC |
-0.014 |
0.7 |